Annual Epidemiological Spotlight on HIV in the North West
2017 data
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.gov.uk/phe
Twitter: @PHE_uk
Facebook: www.facebook.com/PublicHealthEngland

Prepared by: Josh Forde (Field Service, South East & London), Paul Crook (Field Service, South East & London) and Kathy Chandler (Field Service, North West)
For queries relating to this document, please contact: FES.NorthWest@phe.gov.uk

© Crown copyright 2019
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned.

Published March 2019
PHE publications
gateway number: GW-233

PHE supports the UN
Sustainable Development Goals
# Contents

1 Summary 4
   New diagnoses 4
   Late diagnoses 5
   People living with diagnosed HIV 5
   Continuum of HIV care 6
   People living with undiagnosed HIV 6
   HIV testing 6
   Condom use 6
   Stigma 7
   Public health implications 7
   Key messages 10
   Recommendations to the public 11

2 Charts, tables and maps 13

3 What’s happening in the North West? 24

4 Information on data sources 26

5 Further information 28

6 About the Field Service 29

7 Acknowledgements 30
1 Summary

HIV remains an important public health problem in the North West.

New diagnoses

In 2017, an estimated 462 North West residents were newly diagnosed with HIV, accounting for 12% of new diagnoses in England. This represents a fall of 9% from 2016. Nationally, there has been a long-term trend for a decline in the overall number of new diagnoses, due in the main to a fall in the number of new diagnoses in black Africans who have acquired HIV abroad.

The new diagnosis rate for North West residents aged 15 years or older (7.7 per 100,000) was below that of England in 2017 (8.7 per 100,000).

In 2017, 61% of all new diagnoses in North West residents were in gay, bisexual and other men who have sex with men (MSM) (compared to 60% in 2016 and 45% in 2008). The number of MSM resident in the North West newly diagnosed with HIV (284, adjusted for missing information) was 6% lower than in 2008. Of the MSM newly diagnosed with HIV 88% were white and 76% were UK-born. The number of MSM newly diagnosed with HIV has come down more markedly in the past 3 years.

Heterosexual contact was the second largest infection route for new diagnoses in North West residents in 2017 (35%). Infections in African-born persons accounted for 48% of all heterosexually acquired cases in 2017 (n=64), compared to 63% (n=195) in 2008. Infections in UK-born persons accounted for 40% of all heterosexually acquired cases in 2017.

Injecting drug use accounted for 2% of new diagnoses in North West residents.

Black Africans represented 18% of all newly diagnosed North West residents in 2017 (compared to 17% in 2016 and 33% in 2008). A small proportion of new diagnoses in 2017 were in black Caribbeans (1%).

The number of new diagnoses was highest in the 25-34 year age group in both males and females in 2017.
**Late diagnoses**

Reducing late HIV diagnoses is one of the indicators in the Public Health Outcomes Framework. People who are diagnosed late have a 10-fold risk of mortality within 1 year of diagnosis compared to those diagnosed promptly, and they have increased healthcare costs.

It is of particular concern that a large proportion of North West residents with HIV are diagnosed late (44% from 2015 to 2017, compared to 41% in England), as defined by a CD4 count of less than 350 cells/mm$^3$ at diagnosis.

In the North West, heterosexuals were more likely to be diagnosed late (59% of males, 49% of females) than MSM (38%). By ethnic group black Africans were more likely to be diagnosed late than the white population (57% and 42% respectively).

**People living with diagnosed HIV**

The 8,717 people living with diagnosed HIV in the North West in 2017 was 1% higher than 2016 and 59% higher than 2008. This increase is partly due to the effectiveness of HIV treatment, which has reduced the number of deaths from HIV.

The diagnosed prevalence rate of HIV in the North West in 2017 was 1.9 per 1,000 residents aged 15-59 years. This was lower than the 2.3 per 1,000 observed in England as a whole. Five local authorities in the North West had a diagnosed HIV prevalence in excess of 2 per 1,000 population aged 15-59 years in 2017, which is the threshold for expanded HIV testing. They were Blackpool (4.1), Bolton (2), Liverpool (2.2), Manchester (5.8) and Salford (4.7). The diagnosed prevalence rate in Manchester exceeds 5 per 1,000 and is considered extremely high prevalence.

The 2 most common probable routes of transmission for North West residents living with diagnosed HIV in 2017 were sex between men (54%) and sex between men and women (41%).

In 2017, 47% of those living with diagnosed HIV in the North West were aged between 35 and 49 years, and 34% were aged 50 years and over (up from 17% in 2008). Males represented 74% of North West residents living with diagnosed HIV in 2017 and females represented 26%.

In 2017, 67% of North West residents living with diagnosed HIV were white and 24% were black Africans. However, due to the relative sizes of the white and black African populations the rate per 1,000 population aged 15-59 years was much higher in black Africans (47.0 per 1,000) than in the white population (1.3 per 1,000).
Continuum of HIV care

In the North West in 2016, 94% of residents were receiving anti-retroviral treatment. Of these, 95% were virally suppressed (viral load <200) and were very unlikely to pass on HIV, even if having sex without condoms (untransmissible virus).

For North West residents diagnosed in 2017, the proportion starting treatment within 91 days of diagnosis was 75%, compared to 72% in the UK.

People living with undiagnosed HIV

It is estimated that in 2017, 9% (Credible Interval (CrI) 6%-15%) of people living with HIV in the UK, excluding London, were undiagnosed. This equates to an estimated 5,800 (CrI 3,800-10,100) undiagnosed people.

It is estimated that 3,100 MSM in the UK, outside London, are undiagnosed (CrI 1,500-7,300) and 2,300 heterosexuals (CrI 1,800-3,700), including 1,000 black Africans.

In the UK, outside London, the proportion undiagnosed varied by exposure group with the highest proportion undiagnosed among people living with HIV who inject drugs (10%, CrI 5%-18%), who are MSM (9%, CrI 5%-16%) and who are non-black-African heterosexual men (10%, CrI 6%-25%).

HIV testing

A total of 115,846 HIV tests were conducted in specialist sexual health services (SHSs) in the North West, an increase of 3% since 2013. The HIV testing coverage at specialist SHSs in the North West was 51%, which compares to 66% across England. HIV testing coverage in specialist SHSs in the North West is higher in heterosexual men (71%) than heterosexual women (40%), and highest in MSM (86%).

Condom use

Condoms are crucial in the prevention of HIV and STIs. However, there is evidence of an increase in condomless anal sex with casual partners since the early 2000s. Additionally, almost half of sexually active young people said they had had sex without condoms with a new partner.

---

Stigma

HIV-related stigma and discrimination can negatively impact quality of life and prevent people from being tested for HIV. In the survey Positive Voices, 1 in 8 (13%) of people in England with HIV said they had not told anyone, other than healthcare professionals, about their HIV status (16% of women and 11% of men). A quarter of people said they had needed help disclosing their HIV status in the previous year (31% of women and 21% men). Of those who needed this help, 40% did not receive it. Stigma (including self-stigma) and discrimination also persist in healthcare settings. In the previous year, due to their HIV status, 16% were worried that they might be treated differently to other patients, 10% had avoided healthcare when they needed it, and 5% felt they were refused healthcare or delayed a treatment or medical procedure.

Public health implications

Free and effective antiretroviral therapy (ART) in the UK has transformed HIV from a fatal infection into a chronic, manageable condition. People living with HIV in the UK can now expect to live into old age if diagnosed promptly. For many people, treatment means 1 daily tablet with no or few side effects.

There are a number of approaches to the prevention of HIV transmission and continued funding in prevention activities remains critical to curb the HIV epidemic. Prevention should be targeted at MSM and black African people who are the population groups most at risk of HIV.

The UK was one of the first countries in Europe to witness a substantive decline in HIV diagnoses in gay and bisexual men. A combination of HIV prevention efforts has been a key reason for the decline. Increased HIV testing has led to earlier diagnosis and once people know they have HIV, they can be linked into care and offered treatment. Successful HIV treatment means HIV diagnosed people with an undetectable viral load cannot pass on the infection to others. Alongside correct and consistent condom use, early diagnosis through testing and treatment of HIV to stop onward transmission, we now have PrEP, an HIV-prevention drug.

Correct and consistent condom use remains an extremely effective way to prevent HIV transmission, however, in the UK, uptake among key populations is insufficient. Work to improve condom use should address underlying factors that lead to risk-taking behaviour, especially among MSM. These are diverse and may include low self-esteem, ‘chemsex’ (the use of drugs before or during planned sexual activity to sustain, enhance, disinhibit or facilitate the experience) and sero-adaptive behaviour (modifying

---

of sexual behaviour based on one’s own HIV sero-status, the perceived HIV sero-status of a sexual partner, and/or differences in risk of transmission by different sexual acts).

While testing and treatment for HIV in the UK is free and available to all, large numbers of people living with HIV remain undiagnosed, and rates of late diagnosis remain high. Late HIV diagnosis is associated with poorer health outcomes, including premature death. Furthermore, since the vast majority of people diagnosed with HIV are effectively treated, most new HIV infections are passed on from persons unaware of their infection.

HIV testing is pivotal in reducing HIV transmission as it decreases the number of people living with HIV who are unaware of their infection. Due to the relatively high numbers of MSM and black Africans who remain undiagnosed, HIV testing is particularly important for these groups and in MSM, where the incidence remains high. Partner notification following the diagnosis of HIV infection remains a highly effective way to detect undiagnosed HIV infections: in 2017 in England, 4.3% of partners of people diagnosed with HIV were also positive for HIV.

Missed opportunities for testing remain in England are that:³

- less than half of MSM testing for HIV have had at least 1 HIV test at the same service during the previous year (2017)
- less than half of MSM who have had an ano-genital bacterial STI were tested during the year following their STI diagnosis (2017, 4.4% positivity)
- a third of heterosexual women attending sexual and reproductive health (SRH) services were tested for HIV, even though their HIV test positivity was the same as for women attending specialist SHS (2017)
- uptake of testing at prisons is increasing but is low (71% of prisoners eligible were offered and 33% of these accepted a test in 2017/18)
- a high proportion of people who inject drugs in England who access a clinical service in the preceding year had not been tested for HIV (67%) (2017)

Symptoms due to HIV and AIDS may not appear for many years, and people who are unaware of their infection may not feel themselves to be at risk. However, anyone can acquire HIV regardless of age, gender, ethnicity, sexuality or religion, and it is essential to challenge assumptions about who is at risk of HIV. As well as increasing awareness of HIV, efforts to reduce stigma and other socio-cultural barriers that prevent people from testing and seeking long-term care should be strengthened.

HIV Pre-Exposure Prophylaxis (HIV–PrEP) is the use of antiretroviral agents by people who do not have HIV prior to a potential exposure to HIV to prevent acquisition of

infection. Studies have shown that consistent use of HIV-PrEP can be an efficacious and effective prevention intervention. HIV–PrEP has the potential, within a combination prevention approach, to have a significant role in the control of HIV transmission. The first phase of implementation is the 3-year clinical trial, launched in October 2017, which aims to recruit 13,000 participants in England. As of October 2018, almost 9,000 participants had been recruited.

It has been demonstrated that the advantages of ART extend beyond personal clinical benefit. It is now widely understood that effective HIV treatment results in an ‘undetectable’ viral load which protects individuals living with HIV from passing on the virus to others. The key message is that Undetectable = Untransmittable (U=U): Medicines to treat HIV can eliminate the risk of sexual and mother-to-child HIV transmission.4 People with HIV who maintain an undetectable viral load for at least 6 months do not transmit HIV.

Revised guidelines from the British HIV Association and World Health Organisation recommend that patients start ART at diagnosis regardless of CD4 count both for clinical benefits and preventing onward transmission.5 People living with HIV and their healthcare providers can discuss starting ART to reduce their risk of transmitting HIV to their sexual partners. The policy of immediate anti-retroviral therapy at HIV diagnosis is being implemented by NHS England which complements the current Treatment as Prevention policy. As a result, the proportion of newly diagnosed people in care starting treatment within 91 days of diagnosis has increased.

As rates of other infections transmitted sexually such as gonorrhoea, syphilis, lymphogranuloma venereum, hepatitis C and *Shigella* have been shown to be higher in MSM who are HIV positive, it is important that MSM living with HIV are specifically made aware of the risks of these infections and how to prevent them.

The population of people living with diagnosed HIV is diversifying and growing older. It is critical that HIV and other services continue to evolve to meet the needs of older people living with HIV including the management of comorbidities and other complex health conditions.

With progressive strengthening of combination prevention (including condom use, expanded HIV testing, prompt ART and availability of PrEP), HIV transmission, AIDS and HIV-related deaths could be eliminated in the UK. The recent encouraging changes are dependent upon sustained prevention efforts. The inconsistencies between groups


and geographies demonstrate that combination prevention needs to be replicated for all those at risk of acquiring of HIV, whoever they are and wherever they live.

Key messages

Although there has been steady progression in implementing combination prevention measures to end the HIV epidemic, and the efforts are having a major effect, there still remain opportunities for further improvements. These key messages have been drawn together to support efforts to reach those living with HIV who are undiagnosed and to maintain high treatment and care standards.

Sexual health services should consider how they can:

- increase HIV test coverage among heterosexual attendees with an STI-related need, including black Africans and people born in countries with high HIV prevalence
- increase HIV test coverage among gay, bisexual and other men who have sex with men, particularly those who have not tested recently or who have recently had a bacterial STI
- increase quarterly testing, including an STI screen, in gay, bisexual and other men who have sex with men if they are having unprotected sex with new or casual partners
- improve notification and testing of partners of heterosexuals and gay and bisexual men newly diagnosed with HIV

General practices and hospitals in high and extremely high prevalence areas should consider how to better implement NICE guidance on offering HIV tests to patients.

Healthcare and other professionals should offer and recommend HIV and HCV tests to any patient who has injected drugs.

Prisons should consider how they can increase their ‘opt-out’ blood-borne virus testing activity for new receptions and transfers.

Local authorities should consider how they can:

- ensure that their population groups at increased risk can access HIV testing online and in community settings
- ensure that all commissioned HIV testing programmes have a well-defined referral pathway to HIV care for all people with a reactive/positive test result
- take account of the combination HIV prevention perspective when commissioning

---

6 PHE. Progress towards ending the HIV epidemic: 2018 report. 2018
HIV care providers should:

- continue to monitor their key clinical indicators for HIV care, especially in people who inject drugs and people aged 15-24 years, to ensure the current high standard is maintained and to improve clinical outcomes
- discuss the individual and public health benefits of treatment with all people newly diagnosed with HIV, offering and recommending immediate ART, in line with the 2015 BHIVA guidelines
- adopt long-term condition care frameworks for the management of HIV to ensure the holistic needs of HIV patients are met, thereby supporting their general health and wellbeing – the focus should be on quality of life, prevention of co-morbidities, and incorporating principles of patient-centred care and self-management already in use for other long-term condition services
- continue to support comprehensive surveillance by reporting to PHE in a timely manner; high quality HIV public health data is essential to monitor progress towards the elimination of HIV in the UK

Recommendations to the public

All men who have ever had sex with another man should have an HIV test even if they consider themselves to be heterosexual.

Gay, bisexual and other men who have sex with men should have an HIV test at least annually.

Gay, bisexual and other men who have sex with men should test for HIV and have an STI screen every 3 months if they are having unprotected sex with new or casual partners.

Black African heterosexual men and women, and people born in countries where HIV is common, should have an HIV test, and repeat this every year if having unprotected sex with new or casual partners from countries where HIV is common.

Anyone who is diagnosed with HIV should accept the clinical recommendation that they start treatment immediately. Early treatment initiation enables people living with HIV to live a long and healthy life and minimises the risk of passing the infection to others. HIV treatment is free to all in the UK regardless of immigration or residency status.

A range of methods to prevent HIV acquisition are currently available in the UK. Resources are available that provide guidance on the combination of methods best suited to an individual's health and circumstances.
All HIV testing by the NHS is free and confidential for everyone, regardless of immigration or residency status.

There are many ways to get tested for HIV including:

- going to an STI clinic or a community testing site (www.nhs.uk/Service-Search/HIV-testing/) (www.aidsmap.com/hiv-test-finder)
- asking your GP for an HIV test
- requesting a self-sampling kit online (www.test.hiv/) or obtain a self-testing kit
2 Charts, tables and maps

Figure 1: New HIV diagnoses per 100,000 population aged 15 years or older by PHE centre of residence, 2017

The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.

Figure 2: New HIV diagnoses per 100,000 population aged 15 years or older by upper tier local authority of residence, North West residents, 2017

The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.
Figure 3: New HIV diagnoses and deaths, North West residents and deaths, 2008-2017


The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.

*Numbers may rise as further reports are received. This will impact on interpretation of trends in more recent years.

Figure 4: New HIV diagnoses by probable route of infection (adjusted for missing route of infection information), North West residents, 2008-2017 (please see footnote on interpreting trends)*


The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.

*Numbers may rise as further reports are received and more information is obtained on area of residence of those diagnosed. This is more likely to affect more recent year, particularly 2017. Please see important note on data earlier in this report. This will impact on interpretation of trends in more recent years.
Figure 5: Number of new HIV diagnoses by age group and gender (A) and probable route of infection in males (B), North West residents, 2017

The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.

Figure 6: Number of new HIV diagnoses by ethnic group (adjusted for missing ethnic group information), North West residents, 2008-2017 (please see footnote on interpreting trends)*

The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.

*Numbers may rise as further reports are received and more information is obtained on area of residence of those diagnosed. This is more likely to affect more recent year, particularly 2017. Please see important note on data earlier in this report. This will impact on interpretation of trends in more recent years.
Figure 7: Number of new HIV diagnoses by world region of birth (adjusted for missing world region of birth information), North West residents, 2008-2017 (please see footnote on interpreting trends)*


The number of new diagnoses will depend on accessibility of testing as well as infection and transmission.

*Numbers may rise as further reports are received and more information is obtained on area of residence of those diagnosed. This is more likely to affect more recent year, particularly 2017. Please see important note on data earlier in this report. This will impact on interpretation of trends in more recent years.

Figure 8: Percentage of new HIV diagnoses that were diagnosed late by upper tier local authority of residence, North West, aged 15 years and over, 2015-2017 *


* Only includes new diagnoses for which CD4 count was reported within 91 days of diagnosis; late diagnosis defined as CD4 count <350 cells/mm³. Percentages for UTLAs with fewer than 5 late diagnoses are excluded as the denominator for this calculation is valid new HIV diagnoses which will always be lower than 10,000.

The underlying population will impact on the proportion diagnosed late, for example MSM are less likely to be diagnosed late.
Figure 9: Percentage of new HIV diagnoses that were diagnosed late by probable route of infection (A) and ethnic group (B), North West residents, ages 15 years and over, 2015-2017

(a) Probable exposure category

- Sex between men: 38%
- Het. contact - M: 59%
- Het. contact - F: 49%
- Injecting drug use: 50%

(b) Ethnic group

- White: 42%
- Black African: 57%
- Black Caribbean: 46%


* Only includes new diagnoses for which CD4 count was reported within 91 days of diagnosis; late diagnosis defined as CD4 count <350 cells/mm³.

Figure 10: Diagnosed HIV prevalence per 1,000 residents aged 15-59 years by PHE Centre, 2017

Figure 11: Number of residents living with diagnosed HIV and accessing care, the North West, 2008-2017


Figure 12: Number of residents living with diagnosed HIV and accessing care by probable route of transmission (adjusted for missing information), the North West, 2017

Figure 13: Percentage of residents with diagnosed HIV and accessing care by age group, the North West, 2008 and 2017


Figure 14: Diagnosed HIV prevalence per 1,000 residents by ethnic group aged 15-59 years, the North West, 2017

Figure 15: Diagnosed HIV prevalence per 1,000 residents aged 15-59 years by local authority, the North West, 2017

Figure 16: Diagnosed HIV prevalence per 1,000 residents aged 15-59 years by local authority, the North West, 2017

Figure 17: Diagnosed HIV prevalence per 1,000 residents (all ages) by middle super output area of residence, the North West, 2017

Figure 18: The continuum of HIV care, UK excluding London, 2017

- People living with HIV: 100%
- People diagnosed with HIV: 91%
- On treatment: 88%
- Virally suppressed: 86%

UK outside London
UNAIDS 90:90:90 target
3 What’s happening in the North West?

Ending All New Cases of HIV in Greater Manchester

In Greater Manchester in 2019, a new programme will begin delivery: a starting point for the 25-year ambition to end all new cases of HIV in Greater Manchester.

The Ending All New Cases of HIV programme will have a particular focus on scaling up HIV testing; HIV prevention and support for people living with HIV. The programme aims to amplify and accelerate efforts to reduce transmission of HIV and to tackle late diagnosis.

The key differences to current practice are:

- the targeting of the efforts: Individuals at highest risk of acquiring HIV or disengaging from HIV care will receive tailored support to achieve better sexual health outcomes and a reduction in onward transmission
- a sustained communication and campaign effort to improve awareness: Knowledge and take up of HIV prevention in the form of combination prevention based on behaviour or relationship choices
- the emphasis on co-production by at-risk groups, in the design and delivery of interventions and campaign messages

Monitoring and evaluation will be ongoing in order to understand the effectiveness of interventions and to better understand the opportunities for sustainable development of services.

The work is being funded and mobilised by the Greater Manchester Health and Social Care Partnership (GMHSCP) from their £20 million fund to transform the population health of the city region; steered by the Greater Manchester Sexual Health Network (GMSHN); and in parallel with the implementation of the HIV Fast-Track Cities initiative.

For more information about the Ending All New Cases of HIV programme, please contact:

Victoria Morris
Project Manager – HIV/Sexual Health
Greater Manchester Health and Social Care Partnership
victoria.morris6@nhs.net
HIV Fast-Track Cities

HIV Fast-Track Cities is a global partnership between the City of Paris; the International Association of Providers of AIDS Care (IAPAC); the Joint United Nations Programme on HIV/AIDS (UNAIDS); and the United Nations Human Settlements Programme (UN-Habitat); in collaboration with local, national, regional, and international partners and stakeholders. The initiative was launched on World AIDS Day 2014 in Paris.

Greater Manchester and Liverpool joined the HIV Fast Track Cities network in 2018. Andy Burnham, Mayor of Greater Manchester, announced at the Manchester Pride event in August 2018 that Greater Manchester was joining the HIV Fast Track Cities network. Dr Jose Zuniga from IAPAC attended events in Greater Manchester on the 30th November 2018 and Liverpool on the 1st December 2018 to mark the formal signing of the Paris Declaration. Political leaders and local stakeholders in Liverpool and Greater Manchester have committed to accelerate and scale-up local responses to HIV/AIDS and to work towards achieving and exceeding the UNAIDS 90:90:90 targets.

For more information about the implementation of HIV Fast-Track Cities, please contact:

Greater Manchester:  Dr Orla McQuillan  
Consultant in Genitourinary Medicine  
Northern Sexual Health, Contraception and HIV Service  
Manchester University NHS Foundation Trust  
orla.mquillan@mft.nhs.uk

Liverpool:  James Woolgar  
Sexual Health Commissioning Lead  
Liverpool City Council  
james.woolgar@liverpool.gov.uk
4 Information on data sources

HIV & AIDS New Diagnoses and Deaths (HANDD) collects information on new HIV diagnoses, AIDS at diagnosis and deaths among people diagnosed with HIV. Information is received from laboratories, specialist SHSs, GPs and other services where HIV testing takes place in England, Wales and Northern Ireland. The Recent Infection Testing Algorithm (RITA) and CD4 surveillance scheme are linked to HANDD to assess trends in recent and late diagnoses. Data is deduplicated across regions and therefore figures may differ from country-specific data.

The Survey of Prevalent HIV Infections Diagnosed (SOPHID) began in 1995 and was a cross-sectional survey of all adults living with diagnosed HIV infection who attend for HIV care in England, Wales and Northern Ireland. SOPHID collected information about the individual's place of residence along with epidemiological data including clinical stage and antiretroviral therapy (ART). In 2015, SOPHID reporting in England was replaced by the HIV & AIDS Reporting System (HARS) which captures information at every attendance for HIV care.

Date of data extract: September 2018. Updates to HANDD and SOPHID/HARS made after this date will not be reflected in this report.

Confidence intervals for rates in the figures have been calculated to the 95% level using the Byar's method; confidence intervals for percentages have been calculated to the 95% level using the Wilson Score method (see www.apho.org.uk/resource/item.aspx?RID=48457). Confidence intervals presented in the text are produced by Bayesian analysis.

ONS mid-year estimates for 2017 were used as a denominator for rates for 2017.

The data behind charts showing absolute numbers has been adjusted for missing information; however, unless stated otherwise, the numbers in the summary section are the numbers as reported, that is unadjusted counts. Where charts are displaying adjusted data this is indicated in the chart title.

The denominators for all percentages exclude records for which information was unknown, that is the proportion of new diagnoses where probable route of infection was sex between men would be calculated using new diagnoses for which route of infection was known as the denominator.

With the exception of Figure 3, all analyses in this report are residence-based. Information about a patient’s place of residence is not collected by HANDD. Reports to this database are cross-linked to the database of people accessing care for HIV, HARS.
If a report could not be linked to a corresponding HARS report, the patient's PHEC of residence (but not their LA of residence) was imputed using the location of the centre at which they were diagnosed where sufficient information about the latter was available.

Imputation was not used to supplement the linkage process in the HIV Spotlight report produced in 2014. This means that the numbers in the new diagnosis section of the report for that year cannot be compared directly with the numbers in this report.

Numbers may change as more information becomes available to assign area of residence to cases and historical data is refreshed accordingly.
5 Further information

Please access the online ‘Sexual and Reproductive Health Profiles’ for further information on a whole range of sexual health indicators:
http://fingertips.phe.org.uk/profile/sexualhealth

For more information on local sexual health data sources please access the PHE guide:
H_data_guide_December_2016_FINALNB081216.pdf

For the annual epidemiological spotlight on STIs in the North West: 2017 data, please access:

For the national HIV report: 2017 data, please access:

Local authorities have access to LA HIV, sexual and reproductive health epidemiology reports (LASERs) and other HIV and STI intelligence via the HIV and STI portal. They should contact FES.NorthWest@phe.gov.uk if they do not have access to this information.

Health Protection Team (HPT) contacts are:
Cheshire & Merseyside: Dr Anjila Shah, Consultant in Health Protection – Anjila.Shah@phe.gov.uk
Cumbria & Lancashire: Rebecca Stretch, Senior Health Protection Nurse - Rebecca.Stretch@phe.gov.uk
Greater Manchester: Dr Matthieu Pegorie, Consultant in Health Protection - Matthieu.Pegorie@phe.gov.uk

North West Sexual Health Facilitator – Jon.Dunn@phe.gov.uk
6 About the Field Service

The Field Service (FS) supports Public Health England Centres and partner organisations through the application of epidemiological methods to inform public health action.

FS does this in 2 main ways, firstly by providing a flexible expert resource, available, as and when needed, to undertake epidemiological investigations for key health protection work and secondly through the expert analysis, interpretation and dissemination of surveillance information to PHE Centres, local health partners, service providers and commissioners of services.

Within the FS network, excellence and innovation is encouraged, we foster academic collaborations and take active part and lead in research, development and training.

You can contact your local FS team at FES.NorthWest@phe.gov.uk.

If you have any comments or feedback regarding this report or the FS, please contact FES.NorthWest@phe.gov.uk.
7 Acknowledgements

We would like to thank:

- local sexual health and HIV clinics for supplying the HIV data
- the Institute of Child Health
- PHE Centre for Infectious Disease Surveillance and Control (CIDSC) HIV and STI surveillance teams for collection, analysis and distribution of data
- Victoria Morris, Project Manager – HIV/Sexual Health, Greater Manchester Health and Social Care Partnership, and Jon Dunn, Sexual Health Facilitator for the North West, Public Health England, for providing details for section 3, What’s happening in the North West?